Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-27
2007-03-27
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S544000, C540S553000, C540S582000, C544S002000, C544S063000, C544S089000, C546S112000, C546S113000, C548S200000, C548S311100, C548S452000, C549S032000, C549S377000, C549S396000, C549S462000, C514S211050, C514S212070, C514S230500, C514S252100, C514S300000, C514S366000, C514S387000, C514S412000, C514S453000
Reexamination Certificate
active
10384391
ABSTRACT:
The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 2002/0143182 (2002-10-01), Pfahl et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0144329 (2003-07-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 2005/0014767 (2005-01-01), Pfahl et al.
patent: 2005/0038098 (2005-02-01), Tachdjian et al.
patent: 2005/0070581 (2005-03-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/066167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: WO 02/080935 (2002-10-01), None
Barclay et al., “ortho-Diquaternary aromatic compounds. III. Synthesis and reactions of polyalkyltetralones and derivatives,”Canadian Journal of Chemistry, 48(17):2763-2775 (1970).
Cacchi et al., “Palladium-Catalyzed Triethylammonium Formate Reduction of Aryl Triflates. A Selective Method for the deoxygenation of phenols,”Tetrahedron Letters, 27(45):5541-5544 (1986).
Faul et al., “Synthesis of Novel Retinoid X Receptor-Selective Retinoids,”J. Org. Chem., 66:5772-5782 (2001).
Iwatsuka et al., “General Survey of Diabetic Features of Yellow KK Mice,”Endocrinol. Japon. 17:23-35 (1970).
Xiong et al., “Human D-Type Cyclin,”Cell, 65:691-699 (1991).
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Re., 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc., 121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatmnet of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis, 829-830 (1981).
Blondet et al., “Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-1,2,3,4-Tetrahydro-2-Quinolinone,”Organic Preparation and Procedures Int., 25(2):223-228 (1993).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,”J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci., 87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNF Antibodies on Synovial Cell Interleukin-1 Prodcution in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Cantello et al., “A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-dionesviaRegiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione,”Synlett, 263-264 (1997).
Cantello et al., “The Synthesis of BRL 49653—A Novel and Potent Antihyperglycaemic Agent,”Bioorganic&Medicinal Chemistry Letters, 4:1181-1184 (1994).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters, 39:2933-2936 (1998).
Chang et al., “The Upjohn Colony of KkayMice: A Model for Obese Type II Diabetes,”Elsevier Science Publishers B.V., Biomedical Division, Diabetes, pp. 466-470 (1986).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem., 38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,”Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγAgonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem., 41:5055-5069 (1998).
Coleman “Diabetes-Obesity Syndromes in Mice,”Diabetes, 31(1):1-6 (Apr. 1982).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Dawson et al., “Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity,”J. Med. Chemistry, 38:3368-3383 (1995).
Dawson et al., “The Synthetic Chemistry of Retinoids,”Biology, Chemistry, and Medicine, 2ndEdition, Raven Press, Ltd., New York (1994).
Ebisawa et al., “Novel-Thiazolidinedione Derivatives with Retinoid Synergistic Activity,”Biol. Pharma. Bull., 21(5):547-549 (1998).
Evans et al., “Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetrahedron Letters, 39:2937-2940 (1998).
Farahat et al., “Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis,”Ann. Rheum. Dis., 52: 870-875 (1993).
Ferrell, “Tripping the Switch Fantastic: How A Protein Kinase Cascade Can Convert Graded Inputs into Switch-Like Outputs,”TIBS, 21:460-466 (1996).
Firooznia et al., “Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Coupling Reactions,”Tetrahedron Letters, 40:213-216 (1999).
Förstermann et al., “Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transforming Growth Factor-,”Eur. J. Pharm., 225:161-165 (1992).
Fukuto et al., “Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition,”Annu. Rev. Pharmacol. Toxicol. 35:165-194 (1995).
Gahtan et al
Al-Shamma Hussien A.
Fine Richard M.
Giachino Andrea Fanjul
Guo Jianhua
Jakubowicz-Jaillardon Karine
Coppins Janet
Incyte San Diego Inc.
Needle & Rosenberg P.C.
Ortho -McNeil Pharmaceutical, Inc.
Saeed Kamal A.
LandOfFree
Bicyclic heterocycles for the treatment of diabetes and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heterocycles for the treatment of diabetes and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles for the treatment of diabetes and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727177